UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): June 26, 2006

Aastrom Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Michigan	**0-22025**	**94-3096597**
(State or other jurisdiction of incorporation)	(Commission File No.)	(I.R.S. Employer Identification No.)

24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, Michigan 48106
(Address of principal executive offices)

Registrant's telephone number, including area code:
(734) 930-5555

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit 99.1, which is incorporated herein by reference, is a copy of certain slides used by the Company in making a presentation to analysts and potential investors and that are expected to be used in subsequent presentations to interested parties, including analysts, potential investors and shareholders. This information is not "filed" pursuant to the Securities Exchange Act and is not incorporated by reference into any Securities Act registration statements. Additionally, the submission of this report on Form 8-K is not an admission as to the materiality of any information in this report that is required to be disclosed solely by Regulation FD. Any information in this report supersedes inconsistent or outdated information contained in earlier Regulation FD disclosures.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Slides used in presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2006

AASTROM BIOSCIENCES, INC.

By: /s/ Gerald D. Brennan, Jr.
Gerald D. Brennan, Jr.
Vice President, Administrative and
Financial Operations, CFO

Exhibit 99.1

Aastrom BIOSCIENCES INC

Capturing the Therapeutic Potential of Bone Marrow Stem Cells

Investor Presentation
June, 2006

(Nasdaq:ASTM)

SAFE HARBOR

- This presentation contains forward-looking statements, including, without limitation, statements concerning product-development objectives and anticipated timing, clinical trial strategies, timing and expected results, potential market opportunities and revenue models, market development plans, anticipated key milestones and potential advantages and applications of Tissue Repair Cells (TRCs), which involve certain risks and uncertainties. Actual results may differ significantly from the expectations contained in the forward-looking statements.
- Among the factors that may result in differences are the results obtained from clinical trials and development activities, regulatory approval requirements, competitive conditions and availability of resources.
- These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

Overview

- Pipeline of autologous tissue regeneration products in clinical development
- Proprietary bone marrow stem, progenitor and stromal cell technology: *Tissue Repair Cells ("TRCs")*
- Proprietary manufacturing platform for regulatory compliance
- Clinical trials and development programs in orthopedics, peripheral vascular and cardiac tissue disorders
- Positive clinical results for bone marrow transplants and bone repair
- Established centralized cell manufacturing facilities in Germany and U.S.
- Comprehensive patent estate for bone marrow stem cells and manufacturing devices

Bone Marrow Stem Cells Generate Tissue

Native cells are potent in small numbers in the body



Therapy requires a *Large Number* of bone marrow stem cells

Aastrom BIOSCIENCES INC

The TRC Advantage



Opportunity for TRCs as a regenerative treatment

Aastrom BIOSCIENCES INC

TRC Production Process

Small aspirate from patient	TRCs produced in AastromReplicell® System		TRCs regenerate human tissues
			
Office procedure	Centralized GMP manufacturing facility	Autologous stem cell product in 12 days	225 patients treated to date

Aastrom BIOSCIENCES INC

Commercialization Model



Clinical Development Pipeline



TRC Development Strategy

Bone Graft Indication

- Rationale
  - Market with multiple areas of use
  - May offer earliest/safest market entry for TRCs
- Strategy
  - Complete Phase I/II trials for 3 types of bone
  - Select single indication for registration trial
  - Niche market for severe injury/problem where current care standards failed or are limited

Aastrom BIOSCIENCES INC

TRC Clinical Trial – Bone Grafting

Non-Union Fracture Indication

- Patients who had failed to heal after one or more standard of care treatments
- Phase I/II trial completed (6 treatments)
  - 6/6 positive for bone growth; healing and safety
- Multi-center study ongoing in U.S. (36 patients)
  - Positive interim results reported for first 7 patients
    - 7/7 healed by 6 months and 4/7 by 3 months
  - Completed accruals Q2 CY2006
  - Additional interim results expected in Q3-4 CY2006

Aastrom BIOSCIENCES INC

TRCs for Bone Grafting

Non-Union Fracture Indication



Aastrom BIOSCIENCES INC

Non-Union Fracture Trial

Candidate Patient X-Rays *



* Clinical Situation: Non-union fracture of humerus which failed fixation and autograft (> 8 months)

Non-Union Fracture Trial

Fracture Site with Previous Fixation Removed



Non-Union Fracture Trial

TRCs and Matrix Applied at Fracture Site



TRC Non-Union Fracture Trial



TRC Clinical Trial – Bone Grafting

Spine Fusion Indication

- IND approved for lead U.S. trial
  - Posterolateral lumbar spine fusion (PLF)
  - 5 patients to be evaluated for safety before expanding to multi-centers
- EU trial (lead center) expected Q3-4 CY2006
  - Transforaminal lumbar interbody spine fusion (TLIF)
  - 10 patients for safety and fusion success
- Plan to finalize a registration trial protocol from experience in the lead trials

Aastrom BIOSCIENCES INC

TRC Development Strategy

Osteonecrosis

- Rationale
  - Up to 20,000 patients in U.S. with limited therapeutic options
  - Necrosis of bone, marrow and vascular tissues
    - Leads to collapse of bone
    - TRC capability to generate all 3 tissues
- Other Factors
  - Orphan market opportunity
- Strategy
  - Obtained Orphan Drug Designation from FDA
  - Initiate Phase I/II trial: *CY2006 Milestone*
  - Expand to multi-centers; targeting as a registration trial

Aastrom BIOSCIENCES INC

TRCs for Vascular Tissue

Critical Limb Ischemia Indication



TRCs for Peripheral Vascular Tissue

Regeneration of Blood Vessels in Ischemic Limbs



Sources: U.S. Census 2000; United Nations 2002 World Population Report; Weitz JI, Byrne J, Clagett P, et al. Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. Circulation 1996; 94: 3026-49. *(Data: U.S., EU and Japan)*

Aastrom BIOSCIENCES INC

TRC Development Strategy

Peripheral Arterial Disease (Critical Limb Ischemia Indication)

- Rationale
  - Large market opportunity with limited therapeutic competition
  - Large volume bone marrow injections showing effectiveness
- Strategy
  - Controlled lead trials to determine effect of TRCs on ischemic vasculature
  - Expand trials to establish method of use for therapeutic benefit
  - Targeting as a registration trial

Aastrom BIOSCIENCES INC

Limb Ischemia

Effect of Large Volume Bone Marrow



Figure 5: **Angiographic analysis of collateral vessel formation in patients in group A**
Collateral branches were strikingly increased at (A) knee and upper-tibia and (B) lower-tibia, ankle, and foot before and 24 weeks after marrow implantation. Contrast densities in suprafemoral, posterior-tibial, and dorsal pedal arteries (arrows) are similar before and after implantation.



Fig. 2. Arteriography of the right hand (A, B) and the left hand (C, D). Before bone marrow transplantation (A, C). Comparison of arteriography performed with that performed on day 120 revealed the formation of new collateral vessels and the dilatation of pre-existing vessels (B, D).

Sources: Lancet 360: 427-435, 2002 (left panel)
Eur J. Vasc Endovasc Surg 00, 1-3, 2002 (right panel)

Aastrom BIOSCIENCES INC

TRC Clinical Trial – Peripheral Vascular

Critical Limb Ischemia Indication in Diabetic Patients

- Phase I/II single-center randomized trial initiated in EU (Q4 CY2005)
- 25 patients with severe diabetic limb ischemia
  - 5 patients per arm of study
  - Controls are both bone marrow and standard of care
  - Intramuscular or intra-arterial routes of administration
- U.S. Phase I/II multi-center protocol under development

Aastrom BIOSCIENCES INC

Targeted Milestones

- Initiate Phase I/II osteonecrosis clinical trial
- Initiate Phase I/II multi-center spine fusion clinical trial
- Report additional interim and final patient data from multi-center U.S. fracture clinical trial
- Announce target indication for registration trial for bone regeneration
- Initiate Phase I/II multi-center critical limb ischemia clinical trial
- Initiate Phase I/II cardiac clinical trial

Aastrom BIOSCIENCES INC

Aastrom Balance Sheet Data

	(March 31, 2006 - Proforma *)
• Cash and Investments	$ 46,200,000
• Total Assets	$ 48,000,000
• Debt	$ -0-
• Shareholders' Equity	$ 46,300,000
• Average Cash Usage Per Month	$ 1,200,000

* Per Aastrom Biosciences, Inc. 3rd Q FY2006 Form 10-Q, as filed with the SEC; includes net proceeds of ~$24 million from equity financing completed in April 2006

Aastrom Opportunity

- TRCs are unique as an expanded autologous tissue product with solid tissue, blood vessel and blood cell regeneration capability
- Positive clinical results reported for safety and tissue regeneration
- Proprietary therapeutic product pipeline for a variety of treatment and prevention indications
- Automated, proprietary manufacturing platform enables reliable, commercial-scale cell production
- Active clinical trials designed to enable short-term assessment of results

Aastrom BIOSCIENCES INC

Capturing the Therapeutic Potential of Bone Marrow Stem Cells

Thank you!

(Nasdaq:ASTM)